메뉴 건너뛰기




Volumn 11, Issue 11, 2011, Pages 1541-1552

Aripiprazole treatment for patients with schizophrenia: From acute treatment to maintenance treatment

Author keywords

acute treatment; aripiprazole; maintenance treatment; schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; DEHYDROARIPIPRAZOLE; DRUG METABOLITE; HALOPERIDOL; OLANZAPINE; PALIPERIDONE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

EID: 80054914101     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.151     Document Type: Article
Times cited : (15)

References (73)
  • 1
    • 0035666578 scopus 로고    scopus 로고
    • The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches
    • Lieberman JA, Perkins D, Belger A et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry 50(11), 884-897 (2001)
    • (2001) Biol. Psychiatry , vol.50 , Issue.11 , pp. 884-897
    • Lieberman, J.A.1    Perkins, D.2    Belger, A.3
  • 2
    • 33645922748 scopus 로고    scopus 로고
    • Determinants of real-world functional performance in schizophrenia subjects: Correlations with cognition, functional capacity, and symptoms
    • Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am. J Psychiatry 163(3), 418-425 (2006)
    • (2006) Am. J Psychiatry , vol.163 , Issue.3 , pp. 418-425
    • Bowie, C.R.1    Reichenberg, A.2    Patterson, T.L.3    Heaton, R.K.4    Harvey, P.D.5
  • 3
    • 22144432283 scopus 로고    scopus 로고
    • A systematic review of the prevalence of schizophrenia
    • Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2(5), e141 (2005)
    • (2005) PLoS Med. , vol.2 , Issue.5
    • Saha, S.1    Chant, D.2    Welham, J.3    McGrath, J.4
  • 4
    • 80054888052 scopus 로고    scopus 로고
    • The American Psychiatric Association practice guidelines for the treatment of psychiatric disorders
    • American Psychiatric Association Second Edition. American Psychiatric Publishing Inc., Arlington, VA, USA
    • American Psychiatric Association. The American Psychiatric Association practice guidelines for the treatment of psychiatric disorders. In: Practice Guideline for the Treatment of Patients with Schizophrenia, Second Edition. American Psychiatric Publishing Inc., Arlington, VA, USA, 565-746 (2006)
    • (2006) Practice Guideline for the Treatment of Patients with Schizophrenia , pp. 565-746
  • 5
    • 0022534163 scopus 로고
    • Outcome study of first-episode psychosis. I: Relapse rates after 1 year
    • Rabiner CJ, Wegner JT, Kane JM. Outcome study of first-episode psychosis. I: relapse rates after 1 year. Am. J Psychiatry 143(9), 1155-1158 (1986)
    • (1986) Am. J Psychiatry , vol.143 , Issue.9 , pp. 1155-1158
    • Rabiner, C.J.1    Wegner, J.T.2    Kane, J.M.3
  • 6
    • 0004050325 scopus 로고    scopus 로고
    • Treatment of patients with schizophrenia
    • American Psychiatric Association American Psychiatric Association, Arlington, VA, USA
    • American Psychiatric Association. Treatment of patients with schizophrenia. In: Practice Guidelines for the Treatment of Psychiatric Disorders. American Psychiatric Association, Arlington, VA, USA, 249-440 (2004)
    • (2004) Practice Guidelines for the Treatment of Psychiatric Disorders , pp. 249-440
  • 7
    • 78951471427 scopus 로고    scopus 로고
    • Aripiprazole as adjunctive therapy for patients with major depressive disorder: Overview and implications of clinical trial data
    • Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 25(2), 109-127 (2011)
    • (2011) CNS Drugs , vol.25 , Issue.2 , pp. 109-127
    • Pae, C.U.1    Forbes, A.2    Patkar, A.A.3
  • 8
    • 58049157203 scopus 로고    scopus 로고
    • Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis
    • Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657), 31-41 (2009)
    • (2009) Lancet , vol.373 , Issue.9657 , pp. 31-41
    • Leucht, S.1    Corves, C.2    Arbter, D.3    Engel, R.R.4    Li, C.5    Davis, J.M.6
  • 9
    • 50349086333 scopus 로고    scopus 로고
    • Neuropharmacology of second-generation antipsychotic drugs: A validity of the serotonin-dopamine hypothesis
    • Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog. Brain Res. 172, 199-212 (2008)
    • (2008) Prog. Brain Res. , vol.172 , pp. 199-212
    • Kuroki, T.1    Nagao, N.2    Nakahara, T.3
  • 10
    • 0037214276 scopus 로고    scopus 로고
    • Efficacy of newer generation antipsychotics in the treatment of schizophrenia
    • Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28(Suppl. 1), 9-26 (2003)
    • (2003) Psychoneuroendocrinology , vol.28 , Issue.SUPPL. 1 , pp. 9-26
    • Tandon, R.1    Jibson, M.D.2
  • 11
    • 0032751075 scopus 로고    scopus 로고
    • Antipsychotic-induced weight gain: A comprehensive research synthesis
    • Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J Psychiatry 156(11), 1686-1696 (1999)
    • (1999) Am. J Psychiatry , vol.156 , Issue.11 , pp. 1686-1696
    • Allison, D.B.1    Mentore, J.L.2    Heo, M.3
  • 12
    • 79952899018 scopus 로고    scopus 로고
    • A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone
    • Lee SY, Park MH, Patkar AA, Pae CU. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog. Neuropsychopharmacol. Biol. Psychiatry 35(2), 490-496 (2011)
    • (2011) Prog. Neuropsychopharmacol. Biol. Psychiatry , vol.35 , Issue.2 , pp. 490-496
    • Lee, S.Y.1    Park, M.H.2    Patkar, A.A.3    Pae, C.U.4
  • 13
    • 77956421518 scopus 로고    scopus 로고
    • Quetiapine XR: Current status for the treatment of major depressive disorder
    • Pae CU, Sohi MS, Seo HJ et al. Quetiapine XR: current status for the treatment of major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(7), 1165-1173 (2010)
    • (2010) Prog. Neuropsychopharmacol. Biol. Psychiatry , vol.34 , Issue.7 , pp. 1165-1173
    • Pae, C.U.1    Sohi, M.S.2    Seo, H.J.3
  • 14
    • 67649322211 scopus 로고    scopus 로고
    • A review of the safety and tolerability of aripiprazole
    • Pae CU. A review of the safety and tolerability of aripiprazole. Expert Opin. Drug Saf. 8(3), 373-386 (2009)
    • (2009) Expert Opin. Drug Saf. , vol.8 , Issue.3 , pp. 373-386
    • Pae, C.U.1
  • 15
    • 80054901686 scopus 로고    scopus 로고
    • Pravastatin as a therapeutic agent for atypical antipsychotic-induced metabolic syndrome in patients with schizophrenia
    • Pae CU. Pravastatin as a therapeutic agent for atypical antipsychotic-induced metabolic syndrome in patients with schizophrenia. CNS Spectr. 13(5), E1 (2008)
    • (2008) CNS Spectr. , vol.13 , Issue.5
    • Pae, C.U.1
  • 16
    • 0031719842 scopus 로고    scopus 로고
    • Adverse effects of the atypical antipsychotics
    • Collaborative Working Group on Clinical Trial Evaluations
    • Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. J Clin. Psychiatr, 59(Suppl. 12), 17-22 (1998)
    • (1998) J Clin. Psychiatr , vol.59 , Issue.SUPPL. 12 , pp. 17-22
  • 17
    • 9944225707 scopus 로고    scopus 로고
    • Aripiprazole: A new atypical antipsychotic with a different pharmacological mechanism
    • Naber D, Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog. Neuropsychopharmacol. Biol. Psychiatry 28(8), 1213-1219 (2004)
    • (2004) Prog. Neuropsychopharmacol. Biol. Psychiatry , vol.28 , Issue.8 , pp. 1213-1219
    • Naber, D.1    Lambert, M.2
  • 18
    • 1042291227 scopus 로고    scopus 로고
    • Focus on aripiprazole
    • Green B. Focus on aripiprazole. Curr Med. Res. Opin. 20(2), 207-213 (2004)
    • (2004) Curr Med. Res. Opin. , vol.20 , Issue.2 , pp. 207-213
    • Green, B.1
  • 19
    • 41949107744 scopus 로고    scopus 로고
    • Aripiprazole in the treatment of depressive and anxiety disorders: A review of current evidence
    • Pae CU, Serretti A, Patkar AA, Masand PS. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 22(5), 367-388 (2008)
    • (2008) CNS Drugs , vol.22 , Issue.5 , pp. 367-388
    • Pae, C.U.1    Serretti, A.2    Patkar, A.A.3    Masand, P.S.4
  • 20
    • 0042887023 scopus 로고    scopus 로고
    • Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology
    • Shapiro DA, Renock S, Arrington E et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28(8), 1400-1411 (2003)
    • (2003) Neuropsychopharmacology , vol.28 , Issue.8 , pp. 1400-1411
    • Shapiro, D.A.1    Renock, S.2    Arrington, E.3
  • 21
    • 2942610711 scopus 로고    scopus 로고
    • Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability
    • DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin. Ther. 26(5), 649-666 (2004)
    • (2004) Clin. Ther. , vol.26 , Issue.5 , pp. 649-666
    • Deleon, A.1    Patel, N.C.2    Crismon, M.L.3
  • 22
    • 10744232425 scopus 로고    scopus 로고
    • Mechanism of new antipsychotic medications: Occupancy is not just antagonism
    • Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch. Gen. Psychiatry 60(10), 974-977 (2003)
    • (2003) Arch. Gen. Psychiatry , vol.60 , Issue.10 , pp. 974-977
    • Grunder, G.1    Carlsson, A.2    Wong, D.F.3
  • 23
    • 0035658175 scopus 로고    scopus 로고
    • Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: Illustrating their mechanism of action
    • Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin. Psychiatr 62(12), 923-924 (2001)
    • (2001) J Clin. Psychiatr , vol.62 , Issue.12 , pp. 923-924
    • Stahl, S.M.1
  • 24
    • 34648830603 scopus 로고    scopus 로고
    • Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: A triple tracer PET study
    • Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am. J Psychiatry 164(9), 1411-1417 (2007)
    • (2007) Am. J Psychiatry , vol.164 , Issue.9 , pp. 1411-1417
    • Mamo, D.1    Graff, A.2    Mizrahi, R.3    Shammi, C.M.4    Romeyer, F.5    Kapur, S.6
  • 25
    • 33845718611 scopus 로고    scopus 로고
    • Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways
    • Urban JD, Vargas GA, von Zastrow M, Mailman RB. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 32(1), 67-77 (2007)
    • (2007) Neuropsychopharmacology , vol.32 , Issue.1 , pp. 67-77
    • Urban, J.D.1    Vargas, G.A.2    Von Zastrow, M.3    Mailman, R.B.4
  • 26
    • 35348854954 scopus 로고    scopus 로고
    • Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912
    • Tadori Y, Kitagawa H, Forbes RA, McQuade RD, Stark A, Kikuchi T. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. Eur J. Pharmacol. 574(2-3), 103-111 (2007)
    • (2007) Eur J. Pharmacol. , vol.574 , Issue.2-3 , pp. 103-111
    • Tadori, Y.1    Kitagawa, H.2    Forbes, R.A.3    McQuade, R.D.4    Stark, A.5    Kikuchi, T.6
  • 27
    • 0036089687 scopus 로고    scopus 로고
    • Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors
    • Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol. Exp. Ther. 302(1), 381-389 (2002)
    • (2002) J Pharmacol. Exp. Ther. , vol.302 , Issue.1 , pp. 381-389
    • Burris, K.D.1    Molski, T.F.2    Xu, C.3
  • 28
    • 0037406258 scopus 로고    scopus 로고
    • Aripiprazole: A new atypical antipsychotic drug
    • Bowles TM, Levin GM. Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother. 37(5), 687-694 (2003)
    • (2003) Ann Pharmacother. , vol.37 , Issue.5 , pp. 687-694
    • Bowles, T.M.1    Levin, G.M.2
  • 29
    • 68349100113 scopus 로고    scopus 로고
    • Formulation optimization of long-acting depot injection of aripiprazole by using D-optimal mixture design
    • Nahata T, Saini TR. Formulation optimization of long-acting depot injection of aripiprazole by using D-optimal mixture design. PDA J. Pharm. Sci. Technol. 63(2), 113-122 (2009)
    • (2009) PDA J. Pharm. Sci. Technol. , vol.63 , Issue.2 , pp. 113-122
    • Nahata, T.1    Saini, T.R.2
  • 30
    • 4344714861 scopus 로고    scopus 로고
    • Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder
    • Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 64(15), 1715-1736 (2004)
    • (2004) Drugs , vol.64 , Issue.15 , pp. 1715-1736
    • Swainston, H.T.1    Perry, C.M.2
  • 32
    • 1642535375 scopus 로고    scopus 로고
    • Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers
    • Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin. Pharmacol. 44(2), 179-187 (2004)
    • (2004) J Clin. Pharmacol. , vol.44 , Issue.2 , pp. 179-187
    • Mallikaarjun, S.1    Salazar, D.E.2    Bramer, S.L.3
  • 33
    • 18944362633 scopus 로고    scopus 로고
    • Aripiprazole: Pharmacology, efficacy, safety and tolerability
    • Kinghorn WA, McEvoy JP. Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev. Neurother. 5(3), 297-307 (2005)
    • (2005) Expert Rev. Neurother. , vol.5 , Issue.3 , pp. 297-307
    • Kinghorn, W.A.1    McEvoy, J.P.2
  • 34
    • 33845713415 scopus 로고    scopus 로고
    • Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients
    • Molden E, Lunde H, Lunder N, Refsum H. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther. Drug Monit. 28(6), 744-749 (2006)
    • (2006) Ther. Drug Monit. , vol.28 , Issue.6 , pp. 744-749
    • Molden, E.1    Lunde, H.2    Lunder, N.3    Refsum, H.4
  • 35
    • 55749106241 scopus 로고    scopus 로고
    • A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia
    • Findling RL, Robb A, Nyilas M et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am. J Psychiatry 165(11), 1432-1441 (2008)
    • (2008) Am. J Psychiatry , vol.165 , Issue.11 , pp. 1432-1441
    • Findling, R.L.1    Robb, A.2    Nyilas, M.3
  • 36
    • 0036738786 scopus 로고    scopus 로고
    • Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
    • Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin. Psychiatr, 63(9), 763-771 (2002)
    • (2002) J Clin. Psychiatr , vol.63 , Issue.9 , pp. 763-771
    • Kane, J.M.1    Carson, W.H.2    Saha, A.R.3
  • 37
    • 0037410337 scopus 로고    scopus 로고
    • Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term, placebo-controlled trials
    • Marder SR, McQuade RD, Stock E et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr. Res. 61(2-3), 123-136 (2003)
    • (2003) Schizophr. Res. , vol.61 , Issue.2-3 , pp. 123-136
    • Marder, S.R.1    McQuade, R.D.2    Stock, E.3
  • 38
    • 0038488945 scopus 로고    scopus 로고
    • Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder
    • Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 60(7), 681-690 (2003)
    • (2003) Arch. Gen. Psychiatry , vol.60 , Issue.7 , pp. 681-690
    • Potkin, S.G.1    Saha, A.R.2    Kujawa, M.J.3
  • 39
    • 9144237416 scopus 로고    scopus 로고
    • Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia
    • Kasper S, Lerman MN, McQuade RD et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J Neuropsychopharmacol. 6(4), 325-337 (2003)
    • (2003) Int. J Neuropsychopharmacol. , vol.6 , Issue.4 , pp. 325-337
    • Kasper, S.1    Lerman, M.N.2    McQuade, R.D.3
  • 40
    • 0141828595 scopus 로고    scopus 로고
    • Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study
    • Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin. Psychiatr. 64(9), 1048-1056 (2003)
    • (2003) J Clin. Psychiatr. , vol.64 , Issue.9 , pp. 1048-1056
    • Pigott, T.A.1    Carson, W.H.2    Saha, A.R.3    Torbeyns, A.F.4    Stock, E.G.5    Ingenito, G.G.6
  • 41
    • 34548189418 scopus 로고    scopus 로고
    • Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks
    • Kane JM, Crandall DT, Marcus RN et al. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr. Res. 95(1-3), 143-150 (2007)
    • (2007) Schizophr. Res. , vol.95 , Issue.1-3 , pp. 143-150
    • Kane, J.M.1    Crandall, D.T.2    Marcus, R.N.3
  • 42
    • 34447117847 scopus 로고    scopus 로고
    • A multicentre randomized naturalistic open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole (STAR) study
    • Kerwin R, Millet B, Herman E et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry 22(7), 433-443 (2007)
    • (2007) Eur Psychiatry , vol.22 , Issue.7 , pp. 433-443
    • Kerwin, R.1    Millet, B.2    Herman, E.3
  • 43
    • 60349130296 scopus 로고    scopus 로고
    • A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia
    • Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol. Psychiatry 65(6), 510-517 (2009)
    • (2009) Biol. Psychiatry , vol.65 , Issue.6 , pp. 510-517
    • Fleischhacker, W.W.1    McQuade, R.D.2    Marcus, R.N.3    Archibald, D.4    Swanink, R.5    Carson, W.H.6
  • 44
    • 16644402581 scopus 로고    scopus 로고
    • A comparison of weight change during treatment with olanzapine or aripiprazole: Results from a randomized, double-blind study
    • McQuade RD, Stock E, Marcus R et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin. Psychiatr, 65(Suppl. 18), 47-56 (2004)
    • (2004) J Clin. Psychiatr , vol.65 , Issue.SUPPL. 18 , pp. 47-56
    • McQuade, R.D.1    Stock, E.2    Marcus, R.3
  • 45
    • 33750614310 scopus 로고    scopus 로고
    • Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: A 52-week, open-label comparison with olanzapine
    • Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl.) 189(2), 259-266 (2006)
    • (2006) Psychopharmacology (Berl.) , vol.189 , Issue.2 , pp. 259-266
    • Chrzanowski, W.K.1    Marcus, R.N.2    Torbeyns, A.3    Nyilas, M.4    McQuade, R.D.5
  • 46
    • 72849140996 scopus 로고    scopus 로고
    • A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy
    • Kane JM, Correll CU, Goff DC et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin. Psychiatr, 70(10), 1348-1357 (2009)
    • (2009) J Clin. Psychiatr , vol.70 , Issue.10 , pp. 1348-1357
    • Kane, J.M.1    Correll, C.U.2    Goff, D.C.3
  • 47
    • 33646818313 scopus 로고    scopus 로고
    • Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia
    • Horacek J, Bubenikova-Valesova V, Kopecek M et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20(5), 389-409 (2006)
    • (2006) CNS Drugs , vol.20 , Issue.5 , pp. 389-409
    • Horacek, J.1    Bubenikova-Valesova, V.2    Kopecek, M.3
  • 48
    • 40549094337 scopus 로고    scopus 로고
    • Intramuscular aripiprazole: A review of its use in the management of agitation in schizophrenia and bipolar i disorder
    • Sanford M, Scott LJ. Intramuscular aripiprazole: a review of its use in the management of agitation in schizophrenia and bipolar I disorder. CNS Drugs 22(4), 335-352 (2008)
    • (2008) CNS Drugs , vol.22 , Issue.4 , pp. 335-352
    • Sanford, M.1    Scott, L.J.2
  • 49
    • 33644828946 scopus 로고    scopus 로고
    • Aripiprazole: Pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia
    • Grunder G, Kungel M, Ebrecht M, Gorocs T, Modell S. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry 39(Suppl. 1), S21-S25 (2006)
    • (2006) Pharmacopsychiatry , vol.39 , Issue.SUPPL. 1
    • Grunder, G.1    Kungel, M.2    Ebrecht, M.3    Gorocs, T.4    Modell, S.5
  • 50
    • 33645053243 scopus 로고    scopus 로고
    • Use of aripiprazole during late pregnancy in a woman with psychotic illness
    • Mendhekar DN, Sharma JB, Srilakshmi P. Use of aripiprazole during late pregnancy in a woman with psychotic illness. Ann Pharmacother. 40(3), 575 (2006)
    • (2006) Ann Pharmacother. , vol.40 , Issue.3 , pp. 575
    • Mendhekar, D.N.1    Sharma, J.B.2    Srilakshmi, P.3
  • 51
  • 52
    • 46749128245 scopus 로고    scopus 로고
    • Elderly patients with dementia-related symptoms of severe agitation and aggression: Consensus statement on treatment options, clinical trials methodology, and policy
    • Salzman C, Jeste DV, Meyer RE et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin. Psychiatr, 69(6), 889-898 (2008)
    • (2008) J Clin. Psychiatr , vol.69 , Issue.6 , pp. 889-898
    • Salzman, C.1    Jeste, D.V.2    Meyer, R.E.3
  • 53
    • 25444518037 scopus 로고    scopus 로고
    • Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: A randomized, placebo-controlled study
    • De Deyn P, Jeste DV, Swanink R et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J Clin. Psychopharmacol. 25(5), 463-467 (2005)
    • (2005) J Clin. Psychopharmacol. , vol.25 , Issue.5 , pp. 463-467
    • De Deyn, P.1    Jeste, D.V.2    Swanink, R.3
  • 54
    • 37849034448 scopus 로고    scopus 로고
    • Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: A multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses
    • Mintzer JE, Tune LE, Breder CD et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am. J Geriatr. Psychiatry 15(11), 918-931 (2007)
    • (2007) Am. J Geriatr. Psychiatry , vol.15 , Issue.11 , pp. 918-931
    • Mintzer, J.E.1    Tune, L.E.2    Breder, C.D.3
  • 55
    • 50349098704 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease
    • Streim JE, Porsteinsson AP, Breder CD et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am. J Geriatr. Psychiatry 16(7), 537-550 (2008)
    • (2008) Am. J Geriatr. Psychiatry , vol.16 , Issue.7 , pp. 537-550
    • Streim, J.E.1    Porsteinsson, A.P.2    Breder, C.D.3
  • 56
    • 22744449459 scopus 로고    scopus 로고
    • Pharmacological management of acute agitation
    • Battaglia J. Pharmacological management of acute agitation. Drugs 65(9), 1207-1222 (2005)
    • (2005) Drugs , vol.65 , Issue.9 , pp. 1207-1222
    • Battaglia, J.1
  • 57
    • 33751247015 scopus 로고    scopus 로고
    • Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: Sub-analysis of a double-blind study
    • Andrezina R, Marcus RN, Oren DA et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Curr Med. Res. Opin. 22(11), 2209-2219 (2006)
    • (2006) Curr Med. Res. Opin. , vol.22 , Issue.11 , pp. 2209-2219
    • Andrezina, R.1    Marcus, R.N.2    Oren, D.A.3
  • 58
    • 33748659860 scopus 로고    scopus 로고
    • Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: A double-blind, placebo-controlled comparison with intramuscular haloperidol
    • Andrezina R, Josiassen RC, Marcus RN et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl.) 188(3), 281-292 (2006)
    • (2006) Psychopharmacology (Berl.) , vol.188 , Issue.3 , pp. 281-292
    • Andrezina, R.1    Josiassen, R.C.2    Marcus, R.N.3
  • 59
    • 33846852409 scopus 로고    scopus 로고
    • Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: A randomized, double-blind, placebo-controlled trial
    • Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin. Psychiatr, 68(1), 111-119 (2007)
    • (2007) J Clin. Psychiatr , vol.68 , Issue.1 , pp. 111-119
    • Tran-Johnson, T.K.1    Sack, D.A.2    Marcus, R.N.3    Auby, P.4    McQuade, R.D.5    Oren, D.A.6
  • 60
    • 57849153895 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia
    • Rappaport SA, Marcus RN, Manos G, McQuade RD, Oren DA. A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia. J Am. Med. Dir. Assoc. 10(1), 21-27 (2009)
    • (2009) J Am. Med. Dir. Assoc. , vol.10 , Issue.1 , pp. 21-27
    • Rappaport, S.A.1    Marcus, R.N.2    Manos, G.3    McQuade, R.D.4    Oren, D.A.5
  • 61
    • 38049002952 scopus 로고    scopus 로고
    • Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: A quantitative review of efficacy and safety
    • Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin. Psychiatr, 68(12), 1876-1885 (2007)
    • (2007) J Clin. Psychiatr , vol.68 , Issue.12 , pp. 1876-1885
    • Citrome, L.1
  • 62
    • 0036244492 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia
    • Breier A, Meehan K, Birkett M et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch. Gen. Psychiatry 59(5), 441-448 (2002)
    • (2002) Arch. Gen. Psychiatry , vol.59 , Issue.5 , pp. 441-448
    • Breier, A.1    Meehan, K.2    Birkett, M.3
  • 63
    • 0034935303 scopus 로고    scopus 로고
    • Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia
    • Wright P, Birkett M, David SR et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am. J Psychiatry 158(7), 1149-1151 (2001)
    • (2001) Am. J Psychiatry , vol.158 , Issue.7 , pp. 1149-1151
    • Wright, P.1    Birkett, M.2    David, S.R.3
  • 64
    • 0034924403 scopus 로고    scopus 로고
    • A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania
    • Meehan K, Zhang F, David S et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin. Psychopharmacol. 21(4), 389-397 (2001)
    • (2001) J Clin. Psychopharmacol. , vol.21 , Issue.4 , pp. 389-397
    • Meehan, K.1    Zhang, F.2    David, S.3
  • 65
    • 0035012418 scopus 로고    scopus 로고
    • Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial
    • Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl.) 155(2), 128-134 (2001)
    • (2001) Psychopharmacology (Berl.) , vol.155 , Issue.2 , pp. 128-134
    • Daniel, D.G.1    Potkin, S.G.2    Reeves, K.R.3    Swift, R.H.4    Harrigan, E.P.5
  • 66
    • 0035121817 scopus 로고    scopus 로고
    • Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients
    • Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin. Psychiatr. 62(1), 12-18 (2001)
    • (2001) J Clin. Psychiatr. , vol.62 , Issue.1 , pp. 12-18
    • Lesem, M.D.1    Zajecka, J.M.2    Swift, R.H.3    Reeves, K.R.4    Harrigan, E.P.5
  • 67
  • 68
    • 79958233416 scopus 로고    scopus 로고
    • A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia
    • Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am. J Psychiatry 168(6), 603-609 (2011)
    • (2011) Am. J Psychiatry , vol.168 , Issue.6 , pp. 603-609
    • Tiihonen, J.1    Haukka, J.2    Taylor, M.3    Haddad, P.M.4    Patel, M.X.5    Korhonen, P.6
  • 69
    • 0029051754 scopus 로고
    • Cost of relapse in schizophrenia
    • Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr. Bull. 21(3), 419-429 (1995)
    • (1995) Schizophr. Bull. , vol.21 , Issue.3 , pp. 419-429
    • Weiden, P.J.1    Olfson, M.2
  • 70
    • 34248574727 scopus 로고    scopus 로고
    • Partial compliance with antipsychotics and its impact on patient outcomes
    • Narasimhan M, Pae CU, Masand N, Masand P. Partial compliance with antipsychotics and its impact on patient outcomes. Int. J.Psychiatry Clin. Prac. 11(2), 102-111 (2007)
    • (2007) Int. J.Psychiatry Clin. Prac. , vol.11 , Issue.2 , pp. 102-111
    • Narasimhan, M.1    Pae, C.U.2    Masand, N.3    Masand, P.4
  • 71
    • 0343178162 scopus 로고    scopus 로고
    • Medication noncompliance in schizophrenia: Part I. Assessment
    • Weldon PAZ. Medication noncompliance in schizophrenia: Part I. Assessment. J Pract. Psych. Behav. Health 3, 106-110 (1997)
    • (1997) J Pract. Psych. Behav. Health , vol.3 , pp. 106-110
    • Weldon, P.A.Z.1
  • 73
    • 84864405348 scopus 로고    scopus 로고
    • Otsuka Pharmaceutical Co. Ltd
    • Otsuka Pharmaceutical Co., Ltd www.otsuka.co.jp/en/product/


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.